Skip to search formSkip to main contentSkip to account menu

Cytogen 356

Known as: CYT 356, CYT-356 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Capromab Pendetide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Role of ProstaScint® for brachytherapy in localized prostate adenocarcinoma
ProstaScint® (CYT-356 or capromab pendetide, Cytogen) is an 111In-labeled monoclonal mouse antibody specific for prostate… 
2000
2000
Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.
PURPOSE Indium 111 capromab pendetide radioimmunoscintigraphy (ProstaScint) has been used to detect occult recurrent carcinoma… 
Highly Cited
1998
Highly Cited
1998
Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy.
Highly Cited
1997
Highly Cited
1997
Monoclonal antibody 7E11.C5 staining of viable LNCaP cells
Prostate‐specific membrane antigen (PSMA) is a transmembrane glycoprotein defined by the monoclonal antibody 7E11.C5. The 7E11.C5… 
Highly Cited
1997
Highly Cited
1997
Comparison of serum PSMA, PSA levels with results of cytogen‐356 ProstaScint® scanning in prostatic cancer patients
Stored serum from clinical trial cases undergoing ProstaScint® (CYT‐356) scanning were available for Prostate Specific Membrane… 
Highly Cited
1996
Highly Cited
1996
Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation.
The utility of monoclonal antibody (MAb) imaging for detection of occult recurrent prostate cancer was investigated in 14… 
Highly Cited
1996
Highly Cited
1996
Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer.
To evaluate whether In-111 capromab pendetide (an antibody conjugate directed to a glycoprotein found primarily on the cell… 
1995
1995
Radioscintiscanning of prostate cancer
Radioscintiscanning of the prostate has been unsuccessfully attempted in the past 25 years. 65Zinc was an early possibility could… 
1994
1994
Prostate cancer imaging with a new monoclonal antibody: A preliminary report
AbstractBackground: Optimal treatment of prostate cancer depends on accurate staging. Computed tomography (CT) and magnetic… 
Highly Cited
1991
Highly Cited
1991
Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356)
A phase 1 study was conducted with the investigational immunoscintigraphic agent, 111In‐CYT‐356, a radiolabeled, site‐specific… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)